雷公藤多甙片治疗异位性皮炎的临床研究

目的:探讨雷公藤多甙片治疗异位性皮炎的有效性。方法:采用随机对照试验方法,将入选的异位性皮炎患者随机分为治疗组30例(予雷公藤多甙片口服)和对照组30例(予开瑞坦片口服),连续口服4周。并通过实验室检测周围血嗜酸粒细胞绝对计数(absolute eosinophil count,AEC)、血清总IgE水平(BA-ELISA方法)、二硝基氯苯(DNCB)以及白细胞介素2(IL-2)。结果:(1)两组治疗4周后临床症状积分比较:治疗组临床症状改善明显优于对照组(P<0.01);(2)两组治疗4周后临床疗效比较:治疗组疗效明显优于对照组(P<0.01);(3)两组随访3个月后临床疗效比较:治疗组疗效明显优于对照组(P<0.01)。(4)两组治疗前、后实验结果比较:AEC、血清IgE水平治疗组较对照组明显降低,DNCB检测的阳性率和IL-2活性治疗组较对照组有显著提高(P<0.01)。结论:雷公藤多甙片可有效治疗异位性皮炎。     

雷公藤多苷治疗IgA肾病30例的临床研究

目的观察雷公藤多苷治疗IgA肾病的疗效。方法将2006年1月～2009年1月在我院门诊或病房就诊的经肾穿刺活检诊断的IgA肾病患者60例随机分为治疗组和对照组各30例。治疗组每天给予雷公藤多苷60mg,日3次,口服;对照组给予依那普利每日10.0mg,日1次,口服。疗程均为12个月。结果雷公藤组有效共计20例,部分有效共计6例,总有效率达86.67%;而对照组有效12例,部分有效7例,总有效率为63.33%。两组总体有效率相比较,差异有统计学意义(P0.05)。治疗组尿蛋白和血清白蛋白较治疗前及对照组治疗后相比均具有统计学意义(P0.05)。结论雷公藤多苷治疗IgA肾病患者能显著降低患者的尿蛋白,提高患者的血清白蛋白,无明显的不良反应,值得临床推广使用。     

昆明山海棠总生物碱对人结肠癌HCT116细胞裸鼠皮下移植瘤生长的影响

目的观察昆明山海棠总生物碱(total alkaloids oftripterygium hypoglaucum hutch,THHta)对人结肠癌HCT116细胞裸鼠皮下移植瘤生长的影响。方法18只Balb/c裸鼠建立人结肠癌HCT116细胞皮下移植瘤模型,瘤体积增至约100mm3时,随机分为对照组、THHta-1(100mg/kg)和THHta-2(200mg/kg)组,实验期间观测皮下移植瘤生长情况及裸鼠体重的变化,计算肿瘤相对增殖率及瘤重抑制率;取肿瘤组织及肝、脾、肾等行病理组织学检查;免疫组化法检测增殖细胞核抗原(proliferation cell nuclear antigen,PCNA)在肿瘤组织中的表达。结果THHta-1组和THHta-2组裸鼠肿瘤体积和重量显著降低,平均抑瘤率为60.4%和80.2%,治疗第21天两组相对肿瘤增殖率均<40%;THHta-1组和THHta-2组肿瘤组织中PCNA阳性细胞率显著低于对照组(P<0.01)。THHta致裸鼠体重减轻但裸鼠肝、脾、肾等组织未见明显病理学改变。结论THHta抑制人结肠癌HCT116细胞裸鼠皮下移植瘤生长,具有体内抗结肠癌活性,其作用...     

Characterization and engineering of the bifunctional N- and O-glucosyltransferase involved in xenobiotic metabolism in plants

The glucosylation of pollutant and pesticide metabolites in plants controls their bioactivity and the formation of subsequent chemical residues. The model plant Arabidopsis thaliana contains >100 glycosyltransferases (GTs) dedicated to small-molecule conjugation and, whereas 44 of these enzymes catalyze the O-glucosylation of chlorinated phenols, only one, UGT72B1, shows appreciable N-glucosylating activity toward chloroanilines. UGT72B1 is a bifunctional O-glucosyltransferase (OGT) and N-glucosyltransferase (NGT). To investigate this unique dual activity, the structure of the protein was solved, at resolutions up to 1.45 A, in various forms including the Michaelis complex with intact donor analog and trichlorophenol acceptor. The catalytic mechanism and basis for O/N specificity was probed by mutagenesis and domain shuffling with an orthologous enzyme from Brassica napus (BnUGT), which possesses only OGT activity. Mutation of BnUGT at just two positions (D312N and F315Y) installed high levels of NGT activity. Molecular modeling revealed the connectivity of these residues to H19 on UGT72B1, with its mutagenesis exclusively defining NGT activity in the Arabidopsis enzyme. These results shed light on the conjugation of nonnatural substrates by plant GTs, highlighting the catalytic plasticity of this enzyme class and the ability to engineer unusual and desirable transfer to nitrogen-based acceptors.     

A new calorie‐free sugar substitute from the leaf of the stevia plant arrives in the UK

Stevia‐based sweeteners are beginning to enter the UK market following approval for use in the European Union in late 2011. Intensely sweet compounds, called steviol glycosides, are purified from the leaves of the stevia plant to result in a sweetener of natural origin that is about 200 times as sweet as sucrose. The scientific community has been aware of stevia for more than 100 years, yet the case for safety was not made until after reliable purity specifications were established and research results were available that closed safety gaps to the satisfaction of regulators. In food and beverage formulations, steviol glycosides exhibit characteristic behaviours and successful formulation is dependent upon understanding and managing these attributes. Steviol glycosides are particularly well suited for a variety of beverage and dairy applications, confectionery and several other foods. This is in part caused by steviol glycosides' high degree of stability in food processing. Stevia‐based sweeteners offer exciting potential for use as an innovative solution for calorie and sugar reduction.     

A randomized,double blind,placebo controlled study to evaluate the effects of ashwagandha (Withania somnifera) extract on sleep quality in healthy adults

ObjectiveNon-restorative sleep (NRS) affects 10% people worldwide, leading to poor sleep quality, as well as physical and cognitive fatigue. This is the first human study in which an extract of ashwagandha (Withania somnifera Dunal L.) was evaluated for effects in improving overall sleep quality in subjects with NRS.MethodsIn this randomized, double-blind, placebo-controlled trial, 150 healthy subjects scoring high on non-restorative sleep measures were given 120 mg of standardized ashwagandha extract (Shoden®) once daily for six weeks. Subjects were evaluated using the Restorative Sleep Questionnaire-weekly version and World Health Organization Quality of Life-Bref (WHOQOL) scale. Sleep actigraphy was used to measure the onset of sleep latency, sleep efficiency, total sleep time and wake after sleep onset. Safety of the treatment was determined by testing of vitals, hematology, biochemistry and urinalysis.ResultsA total of 144 subjects completed the study, with no dropouts due to adverse events. A 72% increase in self-reported sleep quality was found for the treatment group, compared with 29% in the placebo group (p < 0.001). Based on activity monitoring data, the treatment group showed significant improvement in sleep efficiency (SE) (p < 0.01), total sleep time (p < 0.001) and sleep latency (p < 0.01) and wake after sleep onset (WASO) (p < 0.05) versus placebo after six weeks. In the ashwagandha group quality of life (QOL) scores showed significant improvement in physical (p < 0.001), psychological (p < 0.001), and environment domains (p < 0.01).ConclusionsSupplementation with the standardized ashwagandha extract for six weeks improved the overall quality of sleep by significantly improving the NRS condition in healthy subjects. No treatment related adverse events were reported in the study.Trial registrationClinical Trials Registry-India (www.ctri.nic.in). Registration number: CTRI/2017/02/007801.     

糖皮质激素联合雷公藤多苷治疗结缔组织病相关间质性肺疾病的临床观察

目的:观察糖皮质激素联合雷公藤多苷治疗结缔组织病相关间质性肺疾病(connective tissue disease-related interstitial lung disease,CTD-ILD)临床疗效。方法:纳入CTD-ILD患者74例,随机分为激素组和联合组,每组37例。激素组患者采用糖皮质激素治疗,联合组患者采用糖皮质激素联合雷公藤多苷片治疗,观察周期为6个月。评价两组患者的临床疗效,比较两组患者的CT影像学评分、肺功能指标及不良反应发生情况。结果:治疗后,联合组患者的总有效率为67.5%,激素组为40.5%,联合组疗效优于激素组(P0.05);两组患者的喘息、憋气、咳嗽、Velcro啰音积分均降低(P0.05),且联合组患者的各项积分均低于激素组(P0.05);两组患者的CT影像学积分均显著降低(P0.05),且联合组患者的CT影像学积分低于激素组(P0.05);两组患者的肺总量(TLC)、CO弥散量(DLCO)、动脉血氧分压(PaO_2)水平均显著升高(P0.05),且联合组患者的TLC、DLCO、PaO_2水平高于激素组(P0.05)。治疗过程中,两组患者的不良反应发生情况比较,差异无统计学意义(P0.05)。结论:糖皮质激素联合雷公藤多苷治疗CTDILD能够提高治疗效果,且安全性较好。     

Antibacterial Constituents of Ficus barteri Fruits

A bioassay guided investigation of the ethyl acetate extract of the fruit of Ficus barteri Sprague for antibacterial activity has led to the isolation and characterisation of 3,5,4'-trihydroxystilbene (trans-resveratrol), 3,5,3',4'-tetrahydroxystilbene, and catechin. The main antibacterial compound was 3,5,3',4'-tetrahydroxystilbene which has MIC values of 25 µg/ml for Staph. aureus, 50 µg/ml for B. subtilis, and &gt; 400 µg/ml for the Gram negative organisms, E. coli and Ps. aeruginosa.     

雷公藤多苷治疗贝伐珠单抗导致蛋白尿1例

晚期大肠癌是我国常见的恶性肿瘤之一，其发病率和死亡率均位于恶性肿瘤的前列［1］。贝伐珠单抗是重组的人源化单克隆抗体，批准用于晚期大肠癌的治疗。该药临床常见的毒副反应有高血压、蛋白尿、出血、胃肠穿孔、血栓等。本例患者长期应用贝伐珠单抗，现就其毒副反应蛋白尿的治疗报告如下。